The Latest Breaking News from FDA

Stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration’s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta’s gene therapy for Duchenne Muscular Dystrophy.

You’ve probably seen claims that chemical sunscreens are harmful—but what’s the real story behind those warnings? With buzz on social media and litigation around ingredients like oxybenzone, many wonder if they should switch. The latest science offers clarity: chemical filters are absorbed into the bloodstream—but current evidence doesn’t show this…

The debate over cane sugar vs. corn syrup is heating up, raising questions about cost, policy, and, in some cases, soda taxes.

People with experimental brain implants often turn to the treatment as a last resort, hoping to improve their health when everything else has failed

Amazon is everywhere. You can buy almost anything with a few clicks. But not every product on Amazon is as safe or legal as it seems. Some items have led to lawsuits, government warnings, and even criminal charges. These cases matter because they show how online shopping can go wrong.…

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Eduard Yusupov and Diana Fuzailov sold sexual enhancement products online via their company Love Potion, Inc., claiming them to be made from natural ingredients

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…